This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tsutamoto, T. Articles by Adachi, T. Search for Related Content PubMed PubMed Citation Articles by Tsutamoto, T. Articles by Adachi, T.

Circulation, Vol 90, 823-829, Copyright © 1994 by American Heart Association

ARTICLES

Plasma arteriovenous cGMP difference as a useful indicator of nitrate tolerance in patients with heart failure

T Tsutamoto, M Kinoshita, Y Ohbayashi, A Wada, Y Maeda and T Adachi
First Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan.

BACKGROUND: The present study was performed to evaluate the effects of nitroglycerin (GTN) on plasma arteriovenous cGMP production and to compare its hemodynamic effects in patients with congestive heart failure (CHF). We also estimated the potential clinical value of plasma arteriovenous cGMP production as an indicator of nitrate tolerance. METHODS AND RESULTS: Plasma arterial and venous cGMP levels, atrial natriuretic peptide level, and hemodynamic parameters were measured before and after GTN infusion in 14 patients with CHF. Although the plasma levels of arterial cGMP and atrial natriuretic peptide decreased immediately after GTN, the plasma level of venous cGMP did not change. GTN infusion caused a dose-dependent increase in plasma arteriovenous cGMP production, and there was a positive correlation between the decrease of pulmonary capillary wedge pressure and the increase of plasma arteriovenous cGMP production immediately after GTN. Hemodynamic tolerance was observed after both 12 and 24 hours, when plasma arteriovenous GMP production was also attenuated. CONCLUSIONS: These findings indicate that the plasma arteriovenous cGMP difference is a clinical indicator of vasodilatory action of GTN and a useful indicator of nitrate tolerance in patients with CHF.

This article has been cited by other articles:

				P. Lourenco, J. P. Araujo, A. Azevedo, A. Ferreira, and P. Bettencourt The cyclic guanosine monophosphate/B-type natriuretic peptide ratio and mortality in advanced heart failure Eur J Heart Fail, February 1, 2009; 11(2): 185 - 190. [Abstract] [Full Text] [PDF]

				R. Maas, E. Schwedhelm, L. Kahl, H. Li, R. Benndorf, N. Luneburg, U. Forstermann, and R. H. Boger Simultaneous Assessment of Endothelial Function, Nitric Oxide Synthase Activity, Nitric Oxide-Mediated Signaling, and Oxidative Stress in Individuals with and without Hypercholesterolemia Clin. Chem., February 1, 2008; 54(2): 292 - 300. [Abstract] [Full Text] [PDF]

				S. Dikalov, B. Fink, M. Skatchkov, D. Stalleicken, and E. Bassenge Formation of Reactive Oxygen Species by Pentaerithrityltetranitrate and Glyceryl Trinitrate In Vitro and Development of Nitrate Tolerance J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 938 - 944. [Abstract] [Full Text]

				J. Mair, B. Puschendorf, R. H. Boger, and S. M. Bode-Boger Is Measurement of Cyclic Guanosine Monophosphate in Plasma or Urine Suitable for Assessing In Vivo Nitric Oxide Production? • Response Circulation, March 31, 1998; 97(12): 1209 - 1210. [Full Text] [PDF]

				T. Tsutamoto, A. Wada, K. Maeda, T. Hisanaga, Y. Maeda, D. Fukai, M. Ohnishi, Y. Sugimoto, and M. Kinoshita Attenuation of Compensation of Endogenous Cardiac Natriuretic Peptide System in Chronic Heart Failure : Prognostic Role of Plasma Brain Natriuretic Peptide Concentration in Patients With Chronic Symptomatic Left Ventricular Dysfunction Circulation, July 15, 1997; 96(2): 509 - 516. [Abstract] [Full Text]